The treatment landscape of advanced hepatocellular carcinoma (HCC) has become increasingly complex over the past few years [1]. After the decade-long multi-kinase inhibitor (MKI) monopoly of sorafenib and lenvatinib, first-line HCC entered its immunotherapy era with the approval by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) of the combination of the anti-programmed death ligand 1 (PD-L1) monoclonal antibody (mAb) atezolizumab and the anti-vascular endothelial growth factor (VEGF) bevacizumab as first-line treatment for unresectable or metastatic HCC [2].
